Sponsors (3)
The bill concentrates funding and stakeholder-driven guidance to accelerate rare-disease drug development and improve transparency, while imposing modest federal costs and creating risks of staff burden, potential conflicts of interest, and limited legal entitlements for stakeholders.
Patients with rare diseases will get clearer, consensus-driven FDA guidance on clinical trial designs and endpoints, which can speed development and approval of therapies.
Drug sponsors and health systems can rely on multi-stakeholder input to reduce regulatory uncertainty, potentially lowering development time and costs for rare-disease therapies.
Congressional direction to dedicate annual appropriations and a coordinated stakeholder process focuses scarce federal resources on rare disease science and policy.
State governments, hospitals, and other stakeholders may face slower FDA review capacity because staff time for at least four additional meetings per year could divert reviewer resources if staffing isn't increased.
Patients and the public face a risk that steering committees or meetings could be influenced by industry or outside foundations (despite conflict policies), undermining trust in guidance.
Summaries and public statements about how input was used may be limited in legal force and create public expectations that exceed FDA obligations, without creating a formal right to consultation.
Based on analysis of 2 sections of legislative text.
Introduced February 24, 2025 by Doris Matsui · Last progress February 24, 2025
Requires HHS (through FDA) to contract with the Reagan‑Udall Foundation to host at least four externally led, science-focused drug-development meetings each year about distinct rare diseases or groups of rare conditions. The Foundation will form a permanent multistakeholder steering committee, plan meetings with FDA and stakeholders, post transcripts and a stakeholder-reviewed summary within 180 days, and produce an annual report to Congress on meeting topics, FDA participation, and how meeting input was used in regulatory decisions. The law authorizes $1,000,000 per year for two separate program elements (total $2,000,000/year) for FY2026–2030 and includes limits clarifying it does not create legal consultation rights, change confidentiality rules, or alter FDA user-fee or review-cycle obligations.